Factors Affecting the Price of Mylotarg

Mylotarg's (gemtuzumab ozogamicin) significant price stems from several key factors. 

Factors Affecting the Price of Mylotarg

Firstly, the immense research and development (R&D) costs associated with pioneering antibody-drug conjugate technology and conducting rigorous clinical trials, especially for a complex condition like acute myeloid leukemia (AML), are substantial. Secondly, the highly specialized and expensive manufacturing process required to produce the biologic components adds considerable expense. Thirdly, the relatively small patient population for AML limits the ability to spread costs widely. Finally, clinical value and outcomes data demonstrating its efficacy in specific populations, combined with insurance coverage and reimbursement negotiations within different healthcare systems, significantly influence the final price point paid by patients and payers.